L&T Technology Services Limited (LTTS) has introduced a new artificial intelligence-driven platform designed to support advanced respiratory diagnostics. Developed in partnership with NVIDIA, the solution uses digital twin technology to create detailed 3D visualizations of lung anatomy, offering enhanced accuracy in diagnosis and treatment planning.
Technology Overview
The platform integrates LTTS’s medical technology expertise with NVIDIA’s AI capabilities to deliver scalable and responsive tools for healthcare environments. It is designed to improve patient care and support faster clinical decision-making.
Core Platform Features
3D Anatomical Digital Twin
The technology generates a high-resolution digital replica of the lungs, including:
- Airways
- Blood vessels
- Lung lobes
- Lesions and abnormalities
AI-Driven Processing
The system incorporates:
- NVIDIA MONAI for medical image segmentation
- NVIDIA TensorRT for optimized AI inference and accelerated performance
Interactive Guidance Tools
The platform supports bronchoscopy procedures through advanced visualization and navigation assistance.
Real-Time Physiological Simulation
Static scan data is converted into dynamic, evolving lung models, reflecting the patient’s changing condition over time.
Potential Applications
The platform is designed for use in areas such as:
- Pre-surgical planning
- Treatment of respiratory diseases including lung cancer, COPD, and infectious disorders
- Advanced imaging workflows and minimally invasive procedures
Financial Snapshot of LTTS
Recent financial data highlights continued business growth alongside innovation efforts:
| Metric | Current Year (₹ crore) | Previous Year (₹ crore) | Change |
| Total Assets | 9,643.50 | 8,488.50 | 13.61% |
| Current Assets | 6,464.10 | 6,230.30 | 3.75% |
| Total Equity | 6,097.50 | 5,347.80 | 14.02% |
Summary
- LTTS has introduced an AI-powered digital twin solution for respiratory diagnostics in collaboration with NVIDIA.
- The platform offers 3D lung visualization, AI-based medical imaging, real-time simulation, and bronchoscopy assistance.
- It is positioned for use in surgical planning and managing critical respiratory illnesses.
- LTTS continues to report steady financial growth, aligning with its expansion in medical technology innovation.
Disclaimer:
This article is intended solely for educational and informational purposes. The securities or companies mentioned are provided as examples and should not be considered as recommendations. Nothing contained herein constitutes personal financial advice or investment recommendations. Readers are advised to conduct their own research and consult a qualified financial advisor before making any investment decisions.
Investments in securities markets are subject to market risks. Please read all related documents carefully before investing.